Yangon, Myanmar, May 12, 2017 - DKSH Business Unit Healthcare, the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, will provide marketing, sales, distribution and logistics services for Boehringer Ingelheim across pharmacies, hospitals and clinics in Myanmar. The agreement will give patients in Myanmar access to new medicine for vascular diseases, arterial hypertension, cancer and diabetes, thereby improving treatment options. The collaboration is an extension of a partnership that includes Cambodia, Singapore and Thailand.
DKSH has been improving people's lives in Myanmar since 1996. The company has built a distribution network covering all areas of Myanmar, reaching 95 percent of Myanmar's population in less than 24 hours. With a strong dedicated healthcare sales force, DKSH ranks among the largest employers in the country and is the clear number one in all healthcare segments - prescription drugs, over-the-counter drugs and medical devices.
Stephen Walter, Head of Vietnam, Cambodia & Myanmar, Boehringer Ingelheim, said: "DKSH is the right partner to support growth thanks to its experience and expertise in prescription only medicines. The company's knowledge of the Myanmar healthcare market is unmistaken. Moreover, DKSH was chosen for being a reliable partner committed to the highest international compliance and business ethics standards."
Last year, DKSH tripled the size of its healthcare distribution center in Yangon. The upgraded facility, which opened in December 2014, supports clients in responding to the increased demand for healthcare products in one of Asia's last frontier markets.
Phillip Wray, Vice President Healthcare, DKSH Myanmar, added: "The advent of Myanmar's middle class is leading to an improved healthcare system and growing demand for high-quality medicines like those of Boehringer Ingelheim. While strengthening the bonds between both companies, more importantly, the extension of our collaboration will give Myanmar patients access to new medicines in key therapeutic areas."
The agreement with Boehringer Ingelheim in Myanmar will further strengthen DKSH's market position in the region while contributing to the Group's overall earnings and profitability over time.